NCT06665347

Brief Summary

This study will be carried out to evaluate the effect of yoga on psychological aspect and quality of life in premenstrual syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 29, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 30, 2024

Completed
3 days until next milestone

Study Start

First participant enrolled

November 2, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2025

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

July 15, 2025

Status Verified

October 1, 2024

Enrollment Period

8 months

First QC Date

October 29, 2024

Last Update Submit

July 11, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • Assessment of premenstrual symptoms

    It will be assessed using daily record of severity of problems (DRSP). It was used to capture premenstrual symptoms. DRSP contained two parts: symptoms related to menstruation (21 items) and their impairment in daily life (3 items). The symptoms included depression, hopelessness, feelings of worthlessness, increased sleeping, trouble sleeping, feeling overwhelmed, breast tenderness, breast swelling, headache, joint or muscle pain, anger, conflicts or problems with people, anxiety, mood swings, sensitivity to rejection, decreased interest, difficulty concentrating, fatigue, increased appetite, craving specific foods, and feeling out of control All items were rated from 1 ("not at all") to 6 ("extreme"). The higher the score, the more severe the premenstrual symptoms.

    8 weeks

  • Assessment of anxiety

    The spielberger state trait anxiety inventory will be used to assess anxiety for all participants. It is a 40-item self-report measure of anxiety using a 4-point Likert-type scale for each item. It has two scales: State anxiety, i.e. how one feels at the moment; and Trait anxiety, i.e. how one generally feels. Both scales consist of 20 items. its score is ranged from 20-80 on both its two subscales. from 20-37 means no or low anxiety, 38-44 means moderate anxiety and 45-80 means severe anxiety.

    8 weeks

  • Assessment of depression:

    It will be assessed using Beck depression inventory. It is a 21-item, self-rated scale that evaluates key symptoms of depression including mood, pessimism, sense of failure, self-dissatisfaction, guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, social withdrawal, indecisiveness, body image change, work difficulty, insomnia, fatigability, loss of appetite, weight loss, somatic preoccupation, and loss of libido. its score is ranged from 0-63 and the lowest is zero.

    8 weeks

  • Assessment of Quality of life

    the SF-36 questionnaire will be used to assess quality of life for all participants. It consists of 36 questions. The SF-36 assesses eight dimensions that include: physical function, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitation due to emotional problems, and mental health. the score is ranged from 0-100. 1 is for the worse health and 100 for the ideal health.

    8 weeks

  • Assessment of stress level

    A blood sample will be taken from each woman in the two groups at pre-treatment and post-treatment to measure cortisol levels at 8 AM before breakfast for all cases. it will be used as an objective indication of pain level. its normal values are 5 to 25 mcg/dl or 140-690 nmol/L.

    8 weeks

  • Assessment of pain intensity

    It will be assessed using the visual analogue scale (VAS). VAS is a simple and frequently used method for the assessment of variations in intensity of pain. In clinical practice the percentage of pain relief, assessed by VAS, is often considered as a measure of the efficacy of treatment. the scale ranges from 0 to 10 with 0 meaning no pain and 10 meaning severe pain

    8 weeks

Study Arms (2)

Progressive muscle relaxation group

ACTIVE COMPARATOR

All participants in this group will receive progressive muscle relaxation for 8 weeks

Other: Progressive muscle relaxation

Progressive muscle relaxation and Yoga group

EXPERIMENTAL

All participants in this group will receive the same progressive muscle relaxation plus yoga for 8 weeks.

Other: Progressive muscle relaxationOther: Yoga

Interventions

The participants will receive progressive muscle relaxation for 8 weeks. The muscles of the hand, arm, face, shoulder and neck, chest, abdomen, back, thigh and hip, legs and feet will be contracted and relaxed in sequence. The contraction time is 5 seconds (s), and the relaxation time is 10s.

Progressive muscle relaxation and Yoga groupProgressive muscle relaxation group
YogaOTHER

The participants will receive yoga for 30 minutes/session, 3 sessions/week for 8 weeks. The session will begin with 5 minutes for warming up. Twenty minutes of wind relieving position (pavanmuktasana), corpse position (savasana), standing side stretch position, seated forward bend (paschimothanasana), cobra position (bhujangasana), and chair position (utkatasana). Five minutes of cooling down.

Progressive muscle relaxation and Yoga group

Eligibility Criteria

Age18 Years - 25 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Their ages will be ranged from 18 to 25 years old.
  • Their body mass index (BMI) will be less than 30 kg/m².
  • They will be virgin.
  • They will have regular menstrual cycles.
  • They will suffer from Premenstrual syndrome based on daily record of severity of problems.
  • All women will be conscious and free from any medical disease.

You may not qualify if:

  • Women with the following criteria should be excluded from this study:
  • Women with endocrine disturbance.
  • Endometriosis.
  • Pelvic inflammatory disease.
  • Any pelvic pathology conditions.
  • Women had hysterectomy or ovariectomy.
  • Women use medications as contraceptive pills, pain relief drugs and antidepressant drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arwa mohamed Abd El-Wahab

Cairo, Egypt

Location

MeSH Terms

Conditions

Premenstrual Syndrome

Interventions

Autogenic TrainingYoga

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

HypnosisMind-Body TherapiesComplementary TherapiesTherapeuticsPsychotherapyBehavioral Disciplines and ActivitiesSpiritual TherapiesExercise Movement TechniquesPhysical Therapy Modalities

Study Officials

  • Hossam Al Din Kamel, Professor

    Al-Azhar University

    STUDY DIRECTOR
  • khadyga Abdul Aziz, Professor

    Cairo University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 29, 2024

First Posted

October 30, 2024

Study Start

November 2, 2024

Primary Completion

June 15, 2025

Study Completion

June 30, 2025

Last Updated

July 15, 2025

Record last verified: 2024-10

Locations